Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Wei-Sen Lam · SciRah

Researcher profile · Semantic Scholar

Wei-Sen Lam

Share profile

Wei-Sen Lam — researcher profile on SciRah

h-index: 9
Works: 24
Citations: 407

Most-cited papers

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
A. Nowak, W. Lesterhuis, Peey-Sei Kok, Chris Brown +14 more
2020The Lancet Oncology143 citations Open access
Semantic Scholar
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
M. Gutierrez, Wei-Sen Lam, M. Hellmann, M. Gubens +20 more
2023Nature Medicine42 citations
Semantic Scholar
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
A. Nowak, Peey-Sei Kok, W. Lesterhuis, B. Hughes +11 more
2018Journal of Thoracic Oncology40 citations Open access
Semantic Scholar
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam, J. Creaney, F. Chen, W. Chin +10 more
2019Lung Cancer26 citations
Semantic Scholar
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
M. Kesavan, P. Grover, Wei-Sen Lam, P. Claringbold +1 more
2021Endocrine-Related Cancer24 citations
Semantic Scholar
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
Bo Gao, M. Carlino, M. Michael, C. Underhill +18 more
2025JAMA Oncology23 citations Open access
Semantic Scholar
DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
A. Nowak, W. Lesterhuis, B. Hughes, Chris Brown +10 more
201823 citations
Semantic Scholar
Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
Nima Mesbah-Ardakani, Connull Leslie, Fabienne Grieu‐Iacopetta, Wei-Sen Lam +3 more
2017Pigment Cell & Melanoma Research20 citations
Semantic Scholar
Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy
Brendan J Crosby, Robert U. Newton, D. Galvão, D. Taaffe +6 more
2023Cancer Medicine16 citations Open access
Semantic Scholar
Intravitreal dexamethasone implant use as first-line therapy for cancer-associated retinopathy
Joel Mudri, Ravinder Singh Phagura, Wei-Sen Lam, Xia-Ni Wu
2021BMJ Case Reports8 citations Open access
Semantic Scholar
Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H non-colorectal cancers: Results from a phase II trial
M. Carlino, Bo Gao, M. Michael, Henry Marshall +21 more
2025JAMA Oncology7 citations
Semantic Scholar
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
M. Gutierrez, Wei-Sen Lam, M. Hellmann, M. Gubens +20 more
2021Journal for ImmunoTherapy of Cancer7 citations Open access
Semantic Scholar
Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1‐3 tyrosine kinase inhibitor anticancer therapy
J. Charng, M. Attia, S. Arunachalam, Wei-Sen Lam +9 more
2021Clinical and Experimental Ophthalmology7 citations
Semantic Scholar
EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
X. Le, A. Eisert, U. Himpe, C. de Bondt +13 more
2022Journal of Thoracic Oncology4 citations Open access
Semantic Scholar
Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic
Johnathan Soggee, M. Hunt, Barbara O'Callaghan, Wei-Sen Lam +4 more
2022Asia-Pacific Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Malignant Pleural Mesothelioma: Present Status and Future Directions
T. Mineo, A. Vincenzo, Ambrosi Jean-Paul, A. Maree +68 more
20174 citations Open access
Semantic Scholar
P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In: Topic: Mesothelioma and SCLC
A. Nowak, Peey-Sei Kok, A. Livingstone, W. Lesterhuis +4 more
20173 citations Open access
Semantic Scholar
P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress: Topic: Mesothelioma and SCLC
Wei-Sen Lam, Y. C. Gary Lee, J. Creaney, S. Muruganandan +3 more
20172 citations Open access
Semantic Scholar
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.
A. Nagrial, Matteo S. Carlino, A. Gunjur, Michael P Brown +22 more
2026Clinical Cancer Research1 citations Open access
Semantic Scholar
635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
R. Herbst, Wei-Sen Lam, M. Hellmann, M. Gubens +20 more
2022Regular and Young Investigator Award Abstracts1 citations Open access
Semantic Scholar
P1.01-107 KEYNOTE-495/KeyImPaCT: Phase 2 Biomarker-Directed Study of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer
M. Gutierrez, M. Hellmann, M. Gubens, C. Aggarwal +13 more
2019Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
MA23.01 Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study
Wei-Sen Lam, A. Nowak, F. Chen, S. Muruganandan +7 more
2019Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
C. Lee, Y. Soon, R. Jeffree, R. Joshi +8 more
2023JTO Clinical and Research Reports0 citations Open access
Semantic Scholar
Final Results of the Dream Trial: A Phase 2 Trial of Durvalumab with First-Line Chemotherapy in Mesothelioma with a Safety Run-In
A. Nowak, W. Lesterhuis, Peey-Sei Kok, Chris Brown +14 more
20200 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Nowak×9
Invite
A. Nowak — researcher profile on SciRah
W. Lesterhuis×5
Invite
W. Lesterhuis — researcher profile on SciRah
Peey-Sei Kok×5
Invite
Peey-Sei Kok — researcher profile on SciRah
T. John×5
Invite
T. John — researcher profile on SciRah

×5

Invite

S. Yip — researcher profile on SciRah

Invite

M. Stockler — researcher profile on SciRah

Invite

M. Millward — researcher profile on SciRah

Invite

Chris Brown — researcher profile on SciRah

Invite

D. Karikios — researcher profile on SciRah

Invite

N. Pavlakis — researcher profile on SciRah

M. Gutierrez×4

Invite

M. Gutierrez — researcher profile on SciRah

Invite

M. Hellmann — researcher profile on SciRah